Lyell Immunopharma (LYEL)
Develops CAR T-cell candidates for lymphoma and metastatic colorectal cancer.
$15.10
Pre-market+0.14 (+0.94%)
At close$14.96(+2.96%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions76 holders · as of Mar 31, 2026 | 48.87% | 11.97M shares | |
| Insiders10 holders · as of Aug 25, 2026 | 0.90% | 220.0K shares | |
| Strategic holders3 holders · as of Jul 27, 2026 | 21.81% | 5.34M shares | |
| Otherremainder | 28.42% | 6.97M shares |
24.51M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
76 holders · 11.97M shares · 19 new positions · 43 increased · 9 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Arch Venture Management, LLC | 3.25M | 13.25% | +488.1K | May 15, 2026 |
| GSK PLC | 1.51M | 6.17% | 0 | May 14, 2026 |
| Foresite Capital Management Iv, LLC | 800.4K | 3.27% | 0 | May 15, 2026 |
| Orland Properties Ltd | 754.7K | 3.08% | 0 | May 6, 2026 |
| Vanguard Capital Management LLC | 718.2K | 2.93% | +718.2Knew | May 15, 2026 |
| Almitas Capital LLC | 577.8K | 2.36% | 0 | May 15, 2026 |
| Foresite Capital Management V, LLC | 477.1K | 1.95% | 0 | May 15, 2026 |
| Millennium Management LLC | 458.9K | 1.87% | +400.3K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13.90% | 3.25M | 13G | May 15, 2026 ↗ |
| Innovative Cellular Therapeutics Holdings Limited | 12.30% | 3.00M | 13G | Jun 18, 2026 ↗ |
| Innovative Cellular Therapeutics Holdings Ltd | 9.80% | 1.90M | 13G | Nov 13, 2025 ↗ |
| Euler Fund, L.P. | 6.71% | 1.43M | 13G | Apr 21, 2026 ↗ |
| Explore Investments LLC | 6.60% | 1.53M | 13G | May 8, 2026 ↗ |
| Gates Frontier, LLC | 5.60% | 1.04M | 13G | Aug 1, 2025 ↗ |
| Foresite Capital Fund IV, L.P. | 5.40% | 13G | May 15, 2025 ↗ | |
| James Tananbaum (“Tananbaum”)incl. Foresite Capital Fund V, L.P. (“FCF V”), Foresite Capital Management V, LLC (“FCM V”) +4 more | 5.30% | 13G | Oct 31, 2024 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Stephen J. Hillofficer: Chief Operating Officer | Sale | 989 | $15.54 | 16,816 |
| Aug 21, 2026 | Lynn Seelydirector, officer: President and CEO | Sale | 9,589 | $15.54 | 63,899 |
| Aug 21, 2026 | Gary K. Leeofficer: Chief Scientific Officer | Sale | 1,457 | $15.54 | 16,220 |
| Aug 10, 2026 | Gary K. Leeofficer: Chief Scientific Officer | Sale | 131 | $14.34 | 17,677 |
| Aug 10, 2026 | Veronica Sanchez Bulisofficer: VP, Corporate Controller | Sale | 621 | $14.34 | 14,799 |
| Aug 10, 2026 | Stephen J. Hillofficer: Chief Operating Officer | Sale | 89 | $14.34 | 17,805 |
| Aug 10, 2026 | Lynn Seelydirector, officer: President and CEO | Sale | 390 | $14.34 | 73,488 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd10 percent owner | Sale | 10 | $13.70 | 2,857,480 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd10 percent owner | Sale | 10 | $13.73 | 2,857,490 |
| May 11, 2026 | Veronica Sanchez Bulisofficer: VP, Corporate Controller | Sale | 217 | $18.91 | 15,420 |
CongressHouse and Senate disclosures
Not reported.